June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Multicenter study of TNF-a antagonists for refractory Behçet’s uveitis in Spain
Author Affiliations & Notes
  • Marina Mesquida
    Ophthalmology, Hospital Clinic de Barcelona, Barcelona, Spain
  • David Diaz-Valle
    Ophthalmology, Hospital Clinico San Carlos, Madrid, Spain
  • Miguel Cordero Coma
    Ophthalmology, Hospital de León, León, Spain
  • Alejandro Fonollosa
    Ophthalmology, Hospital Universitario Cruces, Bilbao, Spain
  • Victor Llorens
    Ophthalmology, Hospital Clinic de Barcelona, Barcelona, Spain
  • Laura Pelegrin
    Ophthalmology, Hospital Clinic de Barcelona, Barcelona, Spain
  • Maria Victoria Hernandez
    Rheumatology, Hospital Clínic de Barcelona, Barcelona, Spain
  • Gerard Espinosa
    Autoimmune Disease, Hospital Clínic de Barcelona, Barcelona, Spain
  • Blanca Molins
    Ophthalmology, Hospital Clinic de Barcelona, Barcelona, Spain
  • Alfredo Adan Civera
    Ophthalmology, Hospital Clinic de Barcelona, Barcelona, Spain
  • Footnotes
    Commercial Relationships Marina Mesquida, None; David Diaz-Valle, None; Miguel Cordero Coma, Abbott laboratories (R), Merck (R); Alejandro Fonollosa, None; Victor Llorens, None; Laura Pelegrin, None; Maria Victoria Hernandez, None; Gerard Espinosa, None; Blanca Molins, None; Alfredo Adan Civera, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 5192. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Marina Mesquida, David Diaz-Valle, Miguel Cordero Coma, Alejandro Fonollosa, Victor Llorens, Laura Pelegrin, Maria Victoria Hernandez, Gerard Espinosa, Blanca Molins, Alfredo Adan Civera; Multicenter study of TNF-a antagonists for refractory Behçet’s uveitis in Spain. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5192.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To assess the long-term efficacy and safety of tumour necrosis factor alpha (TNF-a) antagonists (infliximab, [IFX]; adalimumab, [ADA]; and golimumab [GLM]) for the treatment of patients with Behçet’s disease (BD) and uveitis who failed to respond or did not tolerate conventional immunosuppressive (IS) treatment.


Retrospective study of patients with Behçet’s uveitis treated with anti-TNF therapy in four tertiary referral hospitals of Spain. Data analyzed were the following: demographic characteristics, disease duration and type of uveitis; best-corrected visual acuity (BCVA); previous treatments; type, regime and duration of each biological agent used; outcomes (remission, loss of efficacy, number of uveitis attacks).


We included 59 eyes of 32 patients (16 males; mean age, 39±11.9 years old) with BD and refractory uveitis. Mean disease duration was 6.4±4.8 years. 18 patients (56.3%) were HLA-B51 positive. 66% of patients had panuveitis, 25% posterior, 6% anterior, and 3% intermediate uveitis. 84% of patients had bilateral ocular involvement. All patients received oral corticosteroids (CS), and 63% had received ≥2 IS drugs at baseline. 25 patients (78%) were treated with IFX and 7 (22%) with ADA as initial therapy. 11/25 patients treated initially with IFX were switched to another anti-TNF agent due to adverse events (3 patients), loss of efficacy (3), patient’s choice (1), or uveitis relapse after IFX withdrawal (4): 9/11 were switched to ADA and 3/11 to GLM. Globally, 16/32 patients were treated with ADA and 3 with GLM. IFX was infused for a mean of 16.6 months (range, 2-48), ADA was administered for a mean of 30.2 months (range, 3-52), and GLM was given for a mean of 4 months (range, 3-6). Mean follow-up was 77.3 months (range, 8-276). 28 (87%) achieved uveitis remission. 12/32 patients were able to discontinue all systemic IS and CS. BCVA remained stable or improved in 53/59 eyes. Mean BCVA improved from 0.2±0.6 to 0.5±0.2 (p<0.05), and ocular attacks per year dropped from 37 in the year before therapy to 5 at final follow-up visit (p<0.05). 3 serious adverse events requiring IFX withdrawal were reported: 1 severe infusion reaction, 1 pulmonary tuberculosis, and 1 prostatitis.


Anti-TNF agents are effective biological drugs for the treatment of Behçet’s uveitis. Treatments were generally well tolerated and only 3 patients required withdrawal.

Keywords: 432 autoimmune disease • 746 uveitis-clinical/animal model • 557 inflammation  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.